NCT02171325Unknown2 期
A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Limiting Toxicity (DLT )in the irinotecan
研究概览
简要总结
The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.
详细描述
To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 65 years, male and female
- •Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )（except metastases only as pleural effusion）
- •No prior chemotherapy
- •Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery
- •With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable)
- •Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1
- •Expected survival ≥ 3months
- •Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of
- •absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L
- •blood platelet(PLT) ≥ 100 × 109 / L
- •Hb≥ 90g / L
- •conjugative bilirubin(CB)≤ upper limit of normal(ULN) × 1.5
- •Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): ≤ upper limit of normal(ULN )× 2.5
- •Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): ≤ ULN × 2.5
- •Serum creatinine: ≤ ULN or calculated creatinine clearance≥ 60 ml / min
- •(PT INR) ≤ ULN × 1.5
- •ECG: no abnormalities in need of treatment
- •No pregnancy or no pregnancy demand at the end of the study within six months
- •Must provide written informed consent.
排除标准
- •Patient have platinum compounds allergy history
- •Patient with active ulcer disease or chronic enteritis patients
- •Primary lesion(s) has (have) been treated by Surgery or radiation
- •Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks
- •Patients with interstitial pneumonia or pulmonary fibrosis
- •Brain metastasis requiring treatment
- •Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion
- •Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome
- •Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure> 3 (NYHA) and severe arrhythmia
研究组 & 干预措施
irinotecan
Experimental
irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
干预措施: irinotecan (Drug)
结局指标
主要结局
Limiting Toxicity (DLT )in the irinotecan
时间窗: up to 18 weeks
次要结局
- Maximum Tolerated Dose(MTD)in the irinotecan(up to 18weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1Metastatic Colorectal CancerNCT01639326Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau96
已完成
1 期
High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant GliomaMalignant GliomaNCT00283556Kentuckiana Cancer Institute30
终止
2 期
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal CancerColorectal CancerNCT01060423Hans-Joachim Schmoll, MD8
Unknown
1 期
Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and AdolescentsAcute LeukemiaNCT01239485Seoul National University Hospital18
已完成
1 期
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic OriginRefractory Solid Tumors in ChildrenNCT00993044Children's Hospital Los Angeles13